Cargando…

The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies

The worldwide outbreak of SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 as a novel human coronavirus, was the worrying news at the beginning of 2020. Since its emergence complicated more than 870,000 individuals and led to more than 43,000 deaths worldwide. Considering to the potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Molaei, Soheila, Dadkhah, Masoomeh, Asghariazar, Vahid, Karami, Chiman, Safarzadeh, Elham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522676/
https://www.ncbi.nlm.nih.gov/pubmed/33429331
http://dx.doi.org/10.1016/j.intimp.2020.107051
_version_ 1783588235599937536
author Molaei, Soheila
Dadkhah, Masoomeh
Asghariazar, Vahid
Karami, Chiman
Safarzadeh, Elham
author_facet Molaei, Soheila
Dadkhah, Masoomeh
Asghariazar, Vahid
Karami, Chiman
Safarzadeh, Elham
author_sort Molaei, Soheila
collection PubMed
description The worldwide outbreak of SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 as a novel human coronavirus, was the worrying news at the beginning of 2020. Since its emergence complicated more than 870,000 individuals and led to more than 43,000 deaths worldwide. Considering to the potential threat of a pandemic and transmission severity of it, there is an urgent need to evaluate and realize this new virus’s structure and behavior and the immunopathology of this disease to find potential therapeutic protocols and to design and develop effective vaccines. This disease is able to agitate the response of the immune system in the infected patients, so ARDS, as a common consequence of immunopathological events for infections with Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2, could be the main reason for death. Here, we summarized the immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2 and therapeutic and prophylactic strategies with a focus on vaccine development and its challenges.
format Online
Article
Text
id pubmed-7522676
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75226762020-09-29 The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies Molaei, Soheila Dadkhah, Masoomeh Asghariazar, Vahid Karami, Chiman Safarzadeh, Elham Int Immunopharmacol Article The worldwide outbreak of SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 as a novel human coronavirus, was the worrying news at the beginning of 2020. Since its emergence complicated more than 870,000 individuals and led to more than 43,000 deaths worldwide. Considering to the potential threat of a pandemic and transmission severity of it, there is an urgent need to evaluate and realize this new virus’s structure and behavior and the immunopathology of this disease to find potential therapeutic protocols and to design and develop effective vaccines. This disease is able to agitate the response of the immune system in the infected patients, so ARDS, as a common consequence of immunopathological events for infections with Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2, could be the main reason for death. Here, we summarized the immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2 and therapeutic and prophylactic strategies with a focus on vaccine development and its challenges. Published by Elsevier B.V. 2021-03 2020-09-29 /pmc/articles/PMC7522676/ /pubmed/33429331 http://dx.doi.org/10.1016/j.intimp.2020.107051 Text en © 2020 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Molaei, Soheila
Dadkhah, Masoomeh
Asghariazar, Vahid
Karami, Chiman
Safarzadeh, Elham
The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
title The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
title_full The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
title_fullStr The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
title_full_unstemmed The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
title_short The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
title_sort immune response and immune evasion characteristics in sars-cov, mers-cov, and sars-cov-2: vaccine design strategies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522676/
https://www.ncbi.nlm.nih.gov/pubmed/33429331
http://dx.doi.org/10.1016/j.intimp.2020.107051
work_keys_str_mv AT molaeisoheila theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT dadkhahmasoomeh theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT asghariazarvahid theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT karamichiman theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT safarzadehelham theimmuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT molaeisoheila immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT dadkhahmasoomeh immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT asghariazarvahid immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT karamichiman immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies
AT safarzadehelham immuneresponseandimmuneevasioncharacteristicsinsarscovmerscovandsarscov2vaccinedesignstrategies